CN101756994A - Preparation method of compound antihypertensive preparation - Google Patents
Preparation method of compound antihypertensive preparation Download PDFInfo
- Publication number
- CN101756994A CN101756994A CN200810155775A CN200810155775A CN101756994A CN 101756994 A CN101756994 A CN 101756994A CN 200810155775 A CN200810155775 A CN 200810155775A CN 200810155775 A CN200810155775 A CN 200810155775A CN 101756994 A CN101756994 A CN 101756994A
- Authority
- CN
- China
- Prior art keywords
- hydrochlorothiazide
- metoprolol
- preparation
- compound preparation
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound preparation for treating hypertension, which comprises 10-100mg of metoprolol and 5-50mg of hydrochlorothiazide. The product of the invention overcomes the defect that a side effect is markedly enhanced caused by increasing the medicament dosage for ensuring the curative effect when the metoprolol and the hydrochlorothiazide are clinically used at present and one medicament is singly used, and provides a new compound preparation. The metoprolol and the hydrochlorothiazide are combined, and the curative effect has synergistic and complementary actions; the tolerance of patients is increased, the compliance is improved, the dosage is decreased, an adverse reaction is lightened, and the compound preparation is convenient to take and has low price.
Description
Technical field
The present invention relates to medical technical field, disclose a kind of preparation method of compound antihypertensive preparation.
Background technology
Hypertension is common cardiovascular disease, is the great public health problem in the global range.China has 100,000,000 hypertensive patients at present approximately.The Epidemiological study result showed in 1991, and China city and rural area hypertension awareness are respectively 36% and 13%, and treatment rate is respectively 17% and 5%, and the form of hypertension prevention and control is quite severe.According to the WTO prediction, will account for 79% of China's cause of death to the year two thousand twenty noninfectious, wherein the cardiovascular diseases will account for the first place.
Treatment hypertension drug commonly used has beta-blocker metoprolol and diuretic hydrochlorothiazide.
Metoprolol (Hydrochlorothiazide), chemistry 1-isopropylamino-3-[by name is right-(2-methoxyethyl) phenoxy group]-2-propanol L (+)-tartrate, molecular formula is (C
15H
25NO
3)
2C
4H
6O
6, molecular weight: 684.82, shown in the structural formula:
The metoprolol structural formula
Metoprolol is a kind of medicine based on β1Shen Shangxiansunengshouti retardation (heart selectivity), therefore is well suited for treatment hypertension and angina pectoris, reduces the incidence rate of myocardial infarction, the mortality rate after the reduction myocardial infarction.This product is owing to the excitement of retardance ectopia cordis pacemaker adrenoreceptor can be used for treating the tachy-arrhythmia that supraventricular tachy-arrhythmia, ventricular arrhythmia, Folium Digitalis Purpureae class and catecholamine cause.This product energy antagonism catecholamine effect can be treated the arrhythmia that hyperthyroidism causes.When therapeutic dose, this product is not obvious to the effect of shrinking bronchus and peripheral vessels, and airway resistance can be increased after indivedual case medications, can correct but add with the β1Shou Ti agonist.Be mainly used in and keep treatment, arrhythmia, hyperthyroidism after treatment hypertension, angina pectoris, the myocardial infarction.
Hydrochlorothiazide (Hydrochlorothiazide), chemistry 6-chloro-3 by name, 4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1, the 1-dioxide, molecular formula is C
7H
8ClN
3O
4S
2, molecular weight: 297.74, shown in the structural formula:
The hydrochlorothiazide structural formula
The main marrow that suppresses is mixed the again absorption of ascending branch cortex portion to Na+ and Cl-, thereby promotes kidney that the drainage of sodium chloride is produced diuresis.Be to imitate diuretic in one.This product also has the effect of faint inhibition carbonic anhydrase, and therefore HCO3-loses lighter in the urine.Appearance effect in oral back 1 hour reached the peak in about 2 hours, kept 12-18 hour.
This product also has hypotensive effect, and can strengthen the hypotensive effect of other depressor.Pressure reduction effect is weak but certain, uses as basic depressor and other depressor compatibilities clinically.Also have antidiuretic activity, reduce diabetes insipidus patient's urine amount, but the too late pituitrin of curative effect, mechanism of action is not quite clear.
Be used for various edema (with better), each phase hypertension and diabetes insipidus clinically to the cardiac edema curative effect.
Single treat hypertension than the strong dose thing and bring some untoward reaction sometimes with a kind of; blood pressure reduces the compensation response that triggers during as single therapy; take medicine after weak, dizzy, drowsiness, tinnitus, nauseating, vomiting, epigastric discomfort, constipation appear in regular meeting; sometimes also phenomenons such as postural hypotension, muscular spasm, insomnia can appear; though these phenomenons mostly dying away in the drug administration process continuously, also can be brought inconvenience to the patient.
Goal of the invention
Product of the present invention has overcome when using metoprolol and hydrochlorothiazide clinically now, is to guarantee that curative effect increases drug dose during singly with a medicine, causes side effect obviously to increase; During drug combination,, and use clinical medicine dose inaccurate, influence the defective of curative effect of medication because of nothing meets the pharmaceutical preparation of drug combination dosage.Metoprolol and hydrochlorothiazide two medicines share, collaborative, complementary action that curative effect has; Reduce consumption, alleviate untoward reaction, taking convenience, cheap.
Summary of the invention
The objective of the invention is to defective, a kind of compound preparation is provided at the prior art existence.
The present invention is achieved by the following technical solutions:
The hypertensive compound preparation of a kind of treatment, contain the component of following dosage:
Metoprolol 10-100mg
Hydrochlorothiazide 5-50mg
A kind of preferred as technique scheme, a kind ofly treat the component that hypertensive compound preparation contains following dosage:
Metoprolol 20-50mg
Hydrochlorothiazide 10-25mg
As the hypertensive compound preparation of a kind of more excellent treatment, it contains the component of following dosage:
Metoprolol 50mg
Hydrochlorothiazide 25mg
Beneficial effect of the present invention is: the present invention is that two kinds of antihypertensive drugs of low dose of use in conjunction are treated hypertensive, better and untoward reaction is less than single with heavy dose of wherein a kind of medicine antihypertensive effect, the treatment of associating lattice can improve efficacy of antihypertensive treatment, in and the untoward reaction that causes of different pharmaceutical, be applicable to that hyperpietic in various degree takes for a long time.
This preparation also contains a certain amount of adjuvant except that containing above two kinds of active drug; In pharmacy procedure, the addition of adjuvant can be determined according to actual needs.
The adjuvant that this preparation is commonly used has: microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, silicon dioxide, Pulvis Talci, lactose, dextrin, magnesium stearate, carboxymethylstach sodium, calcium sulfate etc.
Compound preparation of the present invention can have multiple mode, as compound recipe metoprolol-hydrochlorothiazide tablet (ordinary tablet, slow releasing tablet and other special tablets), compound recipe metoprolol-hydrochlorothiazide capsule dosage forms such as (conventional capsule, slow releasing capsule and other special capsule preparations).
Embodiment 1
A kind of compound preparation, contain following component:
Metoprolol 50mg
Hydrochlorothiazide 25mg
Starch 15mg
Calcium sulfate 8mg
Pulvis Talci 2mg
Present embodiment can be made into compound recipe metoprolol-hydrochlorothiazide tablet, and preparation method can adopt the preparation method of common pharmaceutical preparation.
Claims (3)
1. treat hypertensive compound preparation for one kind, contain the component of following dosage:
Metoprolol 10-100mg
Hydrochlorothiazide 5-50mg.
2. the hypertensive compound preparation of treatment according to claim 1 is characterized in that compound preparation contains the component of following dosage:
Metoprolol 20-50mg
Hydrochlorothiazide 10-25mg.
3. the hypertensive compound preparation of treatment according to claim 2 is characterized in that compound preparation contains the component of following dosage:
Metoprolol 50mg
Hydrochlorothiazide 25mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810155775A CN101756994A (en) | 2008-10-15 | 2008-10-15 | Preparation method of compound antihypertensive preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810155775A CN101756994A (en) | 2008-10-15 | 2008-10-15 | Preparation method of compound antihypertensive preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101756994A true CN101756994A (en) | 2010-06-30 |
Family
ID=42488476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810155775A Pending CN101756994A (en) | 2008-10-15 | 2008-10-15 | Preparation method of compound antihypertensive preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101756994A (en) |
-
2008
- 2008-10-15 CN CN200810155775A patent/CN101756994A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105582028A (en) | Use of antrodia camphorata for treating diseases | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN102379877B (en) | Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof | |
| CN106110310A (en) | A kind of compound for reducing blood suger containing pioglitazone and preparation method thereof | |
| CN102258523A (en) | Compound preparation for treating hypertension and its preparation method | |
| CN101756994A (en) | Preparation method of compound antihypertensive preparation | |
| CN107158347A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating heart disease | |
| CN101756978A (en) | Preparation method of novel compound antihypertensive preparation | |
| CN101756976A (en) | Novel antihypertensive drug | |
| CN103800307A (en) | Medicinal composition for reducing blood pressure and preparation method thereof | |
| CN115243774B (en) | Pharmaceutical composition containing amlodipine, chlorthalidone and amiloride | |
| CN104758293A (en) | Method for preparing novel compound anti-hypertension preparation | |
| CN101756968A (en) | Novel compound antihypertensive drug | |
| CN108014162A (en) | A kind of application of extractive from leaves of persimmon in treatment is had a sleepless night | |
| CN101229156B (en) | Medicine composition used for cardiovascular disorders | |
| CN101596195B (en) | Oral medicine composite for reducing blood pressure | |
| CN101773500B (en) | Antihypertensive medicinal composition | |
| CN107970248A (en) | Isoglycyrrhiza acid is preparing the purposes in treating hypertension drug | |
| CN101756972A (en) | Compound antihypertensive medicament | |
| CN101756974A (en) | Method for preparing antihypertensive preparation | |
| CN101125143A (en) | Hypertension-treating compound medicine | |
| CN102258522A (en) | Compound preparation used for treating hypertension | |
| Solomon et al. | Treatment of essential hypertension with a combination of propranolol and bendrofluazide | |
| CN104758285A (en) | Novel compound anti-hypertensive drug | |
| CN105106666A (en) | Traditional Chinese medicine preparation for preventing and treating hypertensive diseases and method for preparing traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100630 |